177 related articles for article (PubMed ID: 31799686)
1. Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC).
Berretta M; Cobellis G; Franco R; Panarese I; Rinaldi B; Nasti G; Di Francia R; Rinaldi L
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):10139-10150. PubMed ID: 31799686
[TBL] [Abstract][Full Text] [Related]
2. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.
Taketomi A
Int J Clin Oncol; 2016 Apr; 21(2):213-218. PubMed ID: 26899258
[TBL] [Abstract][Full Text] [Related]
3. [Targeted therapies in hepatocellular carcinomas: recent results and future development].
Marijon H; Faivre S; Raymond E
Bull Cancer; 2009 May; 96(5):553-61. PubMed ID: 19467986
[TBL] [Abstract][Full Text] [Related]
4. An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.
Raoul JL; Gilabert M; Adhoute X; Edeline J
Expert Opin Pharmacother; 2017 Oct; 18(14):1467-1476. PubMed ID: 28893090
[TBL] [Abstract][Full Text] [Related]
5. Evolution of systemic treatment for advanced hepatocellular carcinoma.
Wu TC; Shen YC; Cheng AL
Kaohsiung J Med Sci; 2021 Aug; 37(8):643-653. PubMed ID: 34213069
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
[TBL] [Abstract][Full Text] [Related]
7. Novel drugs in clinical development for hepatocellular carcinoma.
Waidmann O; Trojan J
Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic strategies in hepatocellular carcinoma: current status.
Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma.
Song KD; Choi D; Lee JH; Im GH; Yang J; Kim JH; Lee WJ
AJR Am J Roentgenol; 2014 Jun; 202(6):W559-66. PubMed ID: 24848850
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
11. Early development of sunitinib in hepatocellular carcinoma.
Zhu AX; Raymond E
Expert Rev Anticancer Ther; 2009 Jan; 9(1):143-50. PubMed ID: 19105714
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted therapies in hepatocellular carcinoma.
Tanaka S; Arii S
Semin Oncol; 2012 Aug; 39(4):486-92. PubMed ID: 22846865
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
15. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check.
Lee A; Lee FC
Front Med; 2020 Jun; 14(3):273-283. PubMed ID: 31863306
[TBL] [Abstract][Full Text] [Related]
16. Durable complete response of hepatocellular carcinoma after metronomic capecitabine.
Brandi G; de Rosa F; Bolondi L; Agostini V; Di Girolamo S; Nobili E; Biasco G
Tumori; 2010; 96(6):1028-30. PubMed ID: 21388070
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma.
Yan M; Dongmei B; Jingjing Z; Xiaobao J; Jie W; Yan W; Jiayong Z
Sci Rep; 2017 Oct; 7(1):14074. PubMed ID: 29075040
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of hepatocellular carcinoma: present and future.
Chan SL; Yeo W
J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
[TBL] [Abstract][Full Text] [Related]
19. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy.
Lu LC; Shao YY; Chan SY; Hsu CH; Cheng AL
Anticancer Res; 2014 Feb; 34(2):1047-52. PubMed ID: 24511053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
